Mobilisation of recently absorbed 59Fe in ex vivo perfused rat duodena and the influence of iron status and subsequently absorbed chelators.

J Trace Elem Med Biol

Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt, Fachgebiet Tierernährung und Leistungsphysiologie, Technische Universität München, Hochfeldweg 6, D-85350 Freising, Germany.

Published: March 2006

To investigate the effect of subsequently absorbed metal chelators on recently absorbed 59Fe, duodenal segments from iron-deficient and iron-adequate rats were perfused ex vivo until the 59Fe tissue load had reached a steady state. Subsequently, the segments were perfused with 3 model chelators and their iron complexes: nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA) and citrate. Of these, NTA and EDTA bind iron much tighter than citrate, and Fe-NTA complexes exchange iron within seconds while Fe-EDTA complexes need 48 h to reach equilibrium. Duodenal mucosa-to-serosa transport rates were comparable for all 3 chelators and correlated linearly with luminal concentration. Subsequent perfusion with increasing NTA, Fe-NTA(1:2) and EDTA concentrations mobilised increasing amounts of 59Fe from the duodenum. Mobilised 59Fe moved preferentially back into the luminal perfusate in iron-adequate segments. In iron-deficient segments, 59Fe preferentially continued the absorption process across the basolateral membrane. Fe-EDTA(1:1) hardly mobilised any 59Fe back into the lumen, though basolateral transfer increased at high concentrations. Citrate and Fe-citrate(1:1) mobilised 59Fe only at very high concentrations. This behaviour is in accordance with the rules of complex chemistry: strong, fast reacting ligands like NTA show most impact. Slowly reacting complexes like Fe-EDTA(1:1) have little mobilising impact in spite of strong affinity between EDTA and iron. The low affinity between iron and citrate can be compensated by large concentration. Moreover, iron-deficient segments show stronger re-uptake of mobilised 59Fe from the lumen and a stronger transfer of 59Fe from the tissue across the basolateral membrane. Both are compatible with the more marked expression of divalent metal transporter 1 (DMT-1) and IREG-1 at the brushborder and basolateral membrane of iron-deficient enterocytes. The data suggest that iron ions interact with food ligands during their passage from the apical to the basolateral side of duodenal enterocytes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtemb.2005.10.005DOI Listing

Publication Analysis

Top Keywords

mobilised 59fe
16
basolateral membrane
12
59fe
10
absorbed 59fe
8
subsequently absorbed
8
segments iron-deficient
8
59fe tissue
8
iron-deficient segments
8
59fe lumen
8
high concentrations
8

Similar Publications

Pregnancy rates in β-thalassemia are increasing but the risk of complications is higher; thus, better understanding of maternal and fetal iron homeostasis in this disorder is needed. HbbTh3/+ (Th3/+) mice model human β-thalassemia. Both the murine and human diseases are characterized by low hepcidin, high iron absorption, and tissue iron overload, with concurrent anemia.

View Article and Find Full Text PDF

Mobilization of iron from ferritin: new steps and details.

Metallomics

January 2018

Department of Chemistry and Biochemistry, California State University, Fullerton, CA 92834-6866, USA.

Much evidence indicates that iron stored in ferritin is mobilized through protein degradation in lysosomes, but concerns about this process have lingered, and the mechanistic details of its aspects are lacking. In the studies presented here, Fe-labeled ferritin was induced by preloading hepatic (HepG2) cells with radiolabeled Fe. Placing these cells in a medium containing desferrioxamine resulted in the loss of ferritin-Fe, but adding high concentrations of reducing agents or modulating the internal GSH concentration failed to alter the rates of ferritin-Fe release.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer cells require high levels of iron, and studies suggest that iron chelators could serve as effective anti-cancer agents, with Bp4eT showing strong anti-cancer and anti-viral properties.
  • Bp4eT was found to be highly effective against various cancer cell lines, inducing apoptosis and cell cycle arrest, while its metabolites (semicarbazone and amidrazone) demonstrated significantly reduced cytotoxic effects.
  • The study highlights how Bp4eT is metabolized into less active compounds, underscoring its potential in cancer treatment and providing insights into the relationship between the structure and activity of anti-cancer agents.
View Article and Find Full Text PDF

Deferasirox is an orally effective iron (Fe) chelator currently used for the treatment of iron-overload disease and has been implemented as an alternative to the gold standard chelator, desferrioxamine (DFO). Earlier studies demonstrated that DFO exhibits anticancer activity due to its ability to deplete cancer cells of iron. In this investigation, we examined the in vitro and in vivo activity of deferasirox against cells from human solid tumors.

View Article and Find Full Text PDF

Desferrioxamine B (DFOB) conjugates with adamantane-1-carboxylic acid, 3-hydroxyadamantane-1-carboxylic acid, 3,5-dimethyladamantane-1-carboxylic acid, adamantane-1-acetic acid, 4-methylphenoxyacetic acid, 3-hydroxy-2-methyl-4-oxo-1-pyridineacetic acid (N-acetic acid derivative of deferiprone), or 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid (deferasirox) were prepared and the integrity of Fe(III) binding of the compounds was established from electrospray ionization mass spectrometry and RP-HPLC measurements. The extent of intracellular (59)Fe mobilized by the DFOB-3,5-dimethyladamantane-1-carboxylic acid adduct was 3-fold greater than DFOB alone, and the IC(50) value of this adduct was 6- or 15-fold greater than DFOB in two different cell types. The relationship between logP and (59)Fe mobilization for the DFOB conjugates showed that maximal mobilization of intracellular (59)Fe occurred at a logP value approximately 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!